Berger Dietmar 4
4 · GILEAD SCIENCES, INC. · Filed Mar 12, 2026
Research Summary
AI-generated summary of this filing
Gilead (GILD) CMO Dietmar Berger Exercises Options, Receives Awards
What Happened
Dietmar Berger, Chief Medical Officer of Gilead Sciences (GILD), exercised/converted derivatives for 2,133 shares on March 10, 2026, and had 1,063 shares surrendered/withheld to cover tax obligations, yielding $157,919. On the same date he was granted awards totaling 39,890 derivative units (8,415 and 31,475 units as reported). The actions are primarily an option/derivative exercise plus receipt of company awards (not an open‑market purchase or sale for investment).
Key Details
- Transaction date: 2026-03-10; Form 4 filed: 2026-03-12 (filed timely within the typical two-business-day window).
- Exercise/conversion (code M): 2,133 derivative units converted to shares (acquired).
- Tax withholding/payment (code F): 1,063 shares surrendered at $148.56 per share, proceeds reported $157,919 (disposed to cover taxes/exercise costs).
- Additional derivative disposition: 2,133 derivative units are also listed as disposed in the filing (reflecting the conversion/settlement mechanics).
- Grants/awards (code A): 8,415 derivative units and 31,475 derivative units were reported as granted/awarded (total = 39,890 units). The filing shows a $0.00 strike for the 31,475 units as reported.
- Shares owned after the transaction: not specified in the provided filing excerpt.
- Footnotes: F1 = each RSU represents right to one share; F2 = RSUs vest over four years (25% at one year, then 6.25% quarterly); F3 = stock options vest over four years on the same schedule.
Context
- The filing indicates a standard exercise/settlement plus company awards and a share withholding to satisfy tax liabilities — a routine administrative disposition rather than an open‑market sale for investment reasons.
- The granted units appear to be compensation awards (RSUs and/or options subject to vesting); the filing’s footnotes show four‑year vesting schedules.
- For retail investors: awards and exercises by executives typically reflect compensation events and vesting schedules; the tax‑withholding disposition is common and not necessarily a signal of intent to sell remaining holdings.
Insider Transaction Report
Form 4
Berger Dietmar
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-10+2,133→ 20,045 total - Tax Payment
Common Stock
2026-03-10$148.56/sh−1,063$157,919→ 18,982 total - Exercise/Conversion
Restricted Stock Unit
[F1][F2]2026-03-10−2,133→ 39,046 total→ Common Stock (2,133 underlying) - Award
Restricted Stock Unit
[F1][F2]2026-03-10+8,415→ 47,461 total→ Common Stock (8,415 underlying) - Award
Non-qualified Stock Option (Right to Buy)
[F3]2026-03-10+31,475→ 31,475 totalExercise: $148.56Exp: 2036-03-10→ Common Stock (31,475 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- [F2]The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.
- [F3]The stock options have a four-year vesting schedule. 25% of the options vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Signature
/s/ Amy Kim by Power of Attorney for Dietmar Berger|2026-03-12